Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price
Confirmatory Trial Seeks To Show Survival Advantage
Executive Summary
Krazati was approved for second-line NSCLC with labeling that positions it ahead of Lumakras on efficacy, but not safety. Pricing is slightly higher than for Amgen’s drug.
You may also be interested in...
J.P. Morgan Day Two: Playing Up Potential In The Year Ahead
Daily notebook from the J.P. Morgan Healthcare Conference: Small and mid-size companies take the stage to lay out their guidance for the year, while big pharma is pushed on strategy and business development. Updates from GSK, Mirati, Sarepta, Amgen and US FDA commissioner Robert Califf.
Keeping Track: US FDA Oncology Approvals For Ferring’s Gene Therapy Adstiladrin And Mirati’s Targeted Therapy Krazati
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Mirati Forges Path Forward For Adagrasib In mNSCLC Despite Lukewarm Preliminary Early-Stage Data
The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.